Table 1 Patient characteristics at baseline.
Characteristic | Patients, no. (%) | |
|---|---|---|
Cohort A | Cohort B | |
Clinical characteristics | ||
No. of patients | 58 | 101 |
Median age, years (range) | 66 (47–84) | 64 (43–94) |
Gender | ||
Male | 33 (57%) | 41 (41%) |
Female | 25 (43%) | 60 (59%) |
Histology | ||
Adenocarcinoma | 55 (95%) | 96 (95%) |
Adenosquamous carcinoma | 1 (2%) | 3 (3%) |
Not otherwise specified | 2 (3%) | 2 (2%) |
Smoking history | ||
Never | 44 (76%) | 77 (76%) |
Former | 14 (24%) | 24 (24%) |
ECOG | ||
0 | 32 (55%) | 68 (67%) |
1 | 26 (45%) | 33 (33%) |
Stage | ||
III | 4 (7%) | 6 (7%) |
IV | 54 (93%) | 95 (94%) |
Concurrent mutations | ||
Yes | 23 (40%) | 23 (23%) |
No | 35 (60%) | 78 (77%) |
T790M mutation | ||
Yes | 21 (36%) | 18 (18%) |
No | 37 (64%) | 83 (82%) |
Brain metastases | ||
Yes | 18 (31%) | 31 (31%) |
No | 40 (69%) | 70 (69%) |
Liver metastases | ||
Yes | 9 (15%) | 16 (16%) |
No | 49 (85%) | 85 (84%) |
EGFR TKI received | ||
Afatinib | 2 (3%) | 1 (1%) |
Erlotinib | 3 (5%) | 5 (5%) |
Gefitinib | 23 (40%) | 27 (27%) |
Icotinib | 30 (52%) | 65 (64%) |
Osimertinib | 0 (0%) | 3 (3%) |
